1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued

First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued

TRAXV
First Tracks Biotherapeutics, Inc. Ordinary Shares When-IssuedUS flagNASDAQ Global Select
22.51
USD
+3.51
- -
782.20MMarket Cap
2023 Y
2024 Y
Revenue per Share
- -
- -
Basic EPS, GAAP
-3.05
- -
Free Cash Flow per Basic Share
-2.7
- -
Dividend per Share
- -
- -
Book Value per Share
11.82
- -
Tangible Book Value per Share
11.79
- -
Basic Weighted Avg Shares
35
- -
Sales/Revenue/Turnover
- -
- -
Operating Margin (%)
- -
- -
Depreciation Expense
2
2
Net Income, GAAP
-106
-164
Effective Tax Rate (%)
- -
- -
Profit Margin (%)
- -
- -
Working Capital
380
354
LT Debt
16
14
Total Equity
410
392
Return on Invested Capital (%)
- -
- -
Return on Capital (%)
- -
- -
Return on Common Equity (%)
- -
-40.83

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-4.45%
Free Cash Flow
- -
- -
34.49%
Net Income, GAAP
- -
- -
54.22%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
-1.36
-1.45
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Daniel R. Faga
Sector
Healthcare
Industry
Biotechnology
Address
10770 Wateridge Circle San Diego CA United States of America 92121
IPO Date
Apr 6, 2026
CIK
0002091349
Similar Companies
NKGen Biotech, Inc. Warrants (NKGNW)
ESSA Pharma Inc. (EPIX)
Edesa Biotech, Inc. (EDSA)
Veru Inc. (VERU)
Beijing Hotgen Biotech Co., Ltd. (688068.SS)
HOOKIPA Pharma Inc. (HOOK)
Business
First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued, clinical-stage biotechnology company focused on next-generation antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases; products and services include ANB033, a CD122 antagonist in a Phase 1b trial for celiac disease and eosinophilic esophagitis; rosnilimab, a pathogenic T cell depleter completed a Phase 2b trial for rheumatoid arthritis; ANB101, a BDCA2 modulator in a Phase 1a trial; spinoff from AnaptysBio, Inc. in 2026 with planned listing and capital raise; securities trading impact and corporate actions tied to the spin-off and private placement. The company operates as part of the broader AnaptysBio corporate group structure in the biotechnology sector, with headquarters in the United States and operations intended to be global through strategic partnerships and potential collaborations across biotech and pharmaceutical markets. Founding year and primary corporate origin trace to the spin-off arrangement from AnaptysBio, with the new standalone entity commencing operations as of 2026. Subsidiaries or parent relationships align with the post-spin-off corporate framework, positioning First Tracks Biotherapeutics to advance immunology-targeted therapeutics through clinical development and potential commercialization partnerships.